These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34242494)

  • 1. V
    Lommerse J; Plock N; Cheung SYA; Sachs JR
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1092-1106. PubMed ID: 34242494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development.
    Zhu P; Sy SKB; Skerjanec A
    AAPS J; 2018 Mar; 20(2):40. PubMed ID: 29516330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Operating characteristics of stepwise covariate selection in pharmacometric modeling.
    Ahamadi M; Largajolli A; Diderichsen PM; de Greef R; Kerbusch T; Witjes H; Chawla A; Davis CB; Gheyas F
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):273-285. PubMed ID: 31020450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covariate selection in pharmacometric analyses: a review of methods.
    Hutmacher MM; Kowalski KG
    Br J Clin Pharmacol; 2015 Jan; 79(1):132-47. PubMed ID: 24962797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.
    Ribbing J; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):109-34. PubMed ID: 15379381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation.
    Kuemmel C; Yang Y; Zhang X; Florian J; Zhu H; Tegenge M; Huang SM; Wang Y; Morrison T; Zineh I
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):21-28. PubMed ID: 31652029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.
    Sherer EA; Sale ME; Pollock BG; Belani CP; Egorin MJ; Ivy PS; Lieberman JA; Manuck SB; Marder SR; Muldoon MF; Scher HI; Solit DB; Bies RR
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):393-414. PubMed ID: 22767341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactive visualization and communication for increased impact of pharmacometrics.
    Krause A; Gieschke R
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):140S-145S. PubMed ID: 20881227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confidence and Prediction Intervals for Pharmacometric Models.
    Kümmel A; Bonate PL; Dingemanse J; Krause A
    CPT Pharmacometrics Syst Pharmacol; 2018 Jun; 7(6):360-373. PubMed ID: 29388347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development.
    Hill-McManus D; Marshall S; Liu J; Willke RJ; Hughes DA
    Clin Pharmacol Ther; 2021 Jul; 110(1):49-63. PubMed ID: 32936931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of covariate selection methods with correlated covariates: prior information versus data information, or a mixture of both?
    Chasseloup E; Yngman G; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):485-492. PubMed ID: 32661654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visualization concepts to enhance quantitative decision making in drug development.
    Dykstra K; Pugh R; Krause A
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):130S-139S. PubMed ID: 20881226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical utility of pharmacometric models.
    Kumar SS; Biltaji E; Bies R; Sherwin CM
    Br J Clin Pharmacol; 2018 Jul; 84(7):1413-1414. PubMed ID: 29637580
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.
    Lee JY; Garnett CE; Gobburu JV; Bhattaram VA; Brar S; Earp JC; Jadhav PR; Krudys K; Lesko LJ; Li F; Liu J; Madabushi R; Marathe A; Mehrotra N; Tornoe C; Wang Y; Zhu H
    Clin Pharmacokinet; 2011 Oct; 50(10):627-35. PubMed ID: 21895036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decision making with visualizations: a cognitive framework across disciplines.
    Padilla LM; Creem-Regehr SH; Hegarty M; Stefanucci JK
    Cogn Res Princ Implic; 2018 Dec; 3():29. PubMed ID: 30238055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visualization and communication of pharmacometric models with berkeley madonna.
    Krause A; Lowe PJ
    CPT Pharmacometrics Syst Pharmacol; 2014 May; 3(5):e116. PubMed ID: 24872204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reporting guidelines for population pharmacokinetic analyses.
    Dykstra K; Mehrotra N; Tornøe CW; Kastrissios H; Patel B; Al-Huniti N; Jadhav P; Wang Y; Byon W
    J Clin Pharmacol; 2015 Aug; 55(8):875-87. PubMed ID: 26148467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Regression Approach to Visual Predictive Checks for Population Pharmacometric Models.
    Jamsen KM; Patel K; Nieforth K; Kirkpatrick CMJ
    CPT Pharmacometrics Syst Pharmacol; 2018 Oct; 7(10):678-686. PubMed ID: 30058222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling.
    Zwep LB; Duisters KLW; Jansen M; Guo T; Meulman JJ; Upadhyay PJ; van Hasselt JGC
    CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):350-361. PubMed ID: 33792207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.